Track topics on Twitter Track topics that are important to you
CutisPharma's Firvanq, or vancomycin hydrochloride, was approved by the FDA as an oral treatment for patients with Clostridiu -More-
WILMINGTON, Mass. (Jan. 29, 2018) – CutisPharma announced today that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of...
The company's version of the antibiotic is designed to reduce the burden on pharmacists who compound the drug into liquid formulations.
SummaryCutispharma Inc Cutispharma is a pharmaceutical company that develops and markets proprietary drug products. The company offers products such as oral solutions, oral suspensions, suppositories,...
FIRST - Mouthwash BLM
FIRST Dukes Mouthwash Compounding Kit
FIRST Marys Mouthwash
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies...
We have published hundreds of CutisPharma, Inc. news stories on BioPortfolio along with dozens of CutisPharma, Inc. Clinical Trials and PubMed Articles about CutisPharma, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CutisPharma, Inc. Companies in our database. You can also find out about relevant CutisPharma, Inc. Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...